S. 652In Committee
Protecting Patients from Deceptive Drug Ads Act
Establishes civil penalties, disclosure rules, and reporting requirements for deceptive prescription drug promotion on social media and through telehealth
Plain-English overview
What this bill does
Establishes civil penalties, disclosure rules, and reporting requirements for deceptive prescription drug promotion on social media and through telehealth
Key points
- Establish civil penalties
- Require ad risk disclosures
- Require payment reporting
- Authorize FDA market surveillance
Current status
Where it stands
Status
In Committee
Latest action
2025-02-20 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S1129-1130)
Related context
Topics and policy areas
undefinedAdministrative law and regulatory proceduresCivil actions and liabilityCongressional oversightDepartment of Health and Human ServicesGovernment information and archivesHealthHealth technology, devices, supplies